glp 1 and antipsychotics Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol Figure 1 from Glucagon-like peptide-1

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

Other GLP-1 RAs have also shown varying benefits in clinical trials and are summarized in Table 1

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

These side effects are not usually dangerous and tend to improve as treatment continues

Tune in to Well Yes wherever you get your podcasts and join Walter and Sarah as they explore the future of metabolic wellness, one dose at a time.

That level of secrecy has no place in a legitimate medical program